Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotrovimab for Early Treatment of COVID-19 (COMET-ICE)
NCT04545060Phase 3Completed
- Sponsor
- Vir Biotechnology
- Start
- Aug 2020
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 3 trial of sotrovimab in coronavirus disease 2019 (COVID-19), sponsored by Vir Biotechnology. Started Aug 2020; status: completed.
02
Drugs
sotrovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04545060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545060.